TargetMol

Telapristone

Product Code:
 
TAR-T34798
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20°C
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T34798-100mg100mgEnquire
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T34798-500mg500mgEnquire
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Telapristone, is the active metabolite of telapristone acetate (also known as CDB-4124). Telapristone is a selective progesterone receptor modulator (SPRM) being studied for the treatment of certain progesterone-sensitive conditions.
CAS:
198414-30-1
Molecular Weight:
463.61
Purity:
0.98
SMILES:
C[C@@]12[C@]([C@]3(C([C@H](C1)C4=CC=C(N(C)C)C=C4)=C5C(CC3)=CC(=O)CC5)[H])(CC[C@@]2(C(COC)=O)O)[H]

References

Brazert M, Korman MP, Pawelczyk LA. [Applicability of selective progesterone receptor modulators in the treatment of uterine leiomyomata and their future role in the field of gynecology]. Ginekol Pol. 2013 Sep;84(9):794-800. Review. Polish. PubMed PMID: 24191519. Gamarra-Luques CD, Hapon MB, Goyeneche AA, Telleria CM. Resistance to cisplatin and paclitaxel does not affect the sensitivity of human ovarian cancer cells to antiprogestin-induced cytotoxicity. J Ovarian Res. 2014 Apr 27;7:45. doi: 10.1186/1757-2215-7-45. eCollection 2014. PubMed PMID: 24795781; PubMed Central PMCID: PMC4007005. Lee O, Ivancic D, Allu S, Shidfar A, Kenney K, Helenowski I, Sullivan ME, Muzzio M, Scholtens D, Chatterton RT Jr, Bethke KP, Hansen NM, Khan SA. Local transdermal therapy to the breast for breast cancer prevention and DCIS therapy: preclinical and clinical evaluation. Cancer Chemother Pharmacol. 2015 Dec;76(6):1235-46. doi: 10.1007/s00280-015-2848-y. Epub 2015 Nov 11. PubMed PMID: 26560487. Uphouse L, Hiegel C. Allopregnanolone's attenuation of the lordosis-inhibiting effects of restraint is blocked by the antiprogestin, CDB-4124. Pharmacol Biochem Behav. 2014 Jul;122:16-9. doi: 10.1016/j.pbb.2014.03.012. Epub 2014 Mar 18. PubMed PMID: 24650591; PubMed Central PMCID: PMC4099060.